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Abstract: Poly(ADP-ribosyl)ation reactions, carried out by poly(ADP-ribose) polymerases
(PARPs/ARTDs), are reversible posttranslational modifications impacting on numerous cellular pro-
cesses (e.g., DNA repair, transcription, metabolism, or immune functions). PARP1 (EC 2.4.2.30), the
founding member of PARPs, is particularly important for drug development for its role in DNA repair,
cell death, and transcription of proinflammatory genes. Recent studies have established a novel concept
that PARP1 is critically involved in the formation and destabilization of atherosclerotic plaques in experi-
mental animal models and in humans. Reduction of PARP1 activity by pharmacological or molecular ap-
proaches attenuates atherosclerotic plaque development and enhances plaque stability as well as promotes
the regression of pre-established atherosclerotic plaques. Mechanistically, PARP1 inhibition significantly
reduces monocyte differentiation, macrophage recruitment, Sirtuin 1 (SIRT1) inactivation, endothelial
dysfunction, neointima formation, foam cell death, and inflammatory responses within plaques, all of
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which are central to the pathogenesis of atherosclerosis. This article presents an overview of the multiple
roles and underlying mechanisms of PARP1 activation (poly(ADP-ribose) accumulation) in atherosclero-
sis and emphasizes the therapeutic potential of PARP1 inhibition in preventing or reversing atherosclerosis
and its cardiovascular clinical sequalae. C© 2013 Wiley Periodicals, Inc. Med. Res. Rev., 00, No. 00, 1–32, 2013
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1. INTRODUCTION
The major sources of human illness in the first part of the 21st century are cardiovascular
diseases, mental illness, and cancer. There are overlaps in these areas as, for example, state of
well-being is a contributing factor to cardiovascular disease1 and there are interactions between
depression and cardiovascular disease.2 Cardiovascular disease is manifested as heart attacks
and strokes and their clinical consequences include heart failure and neurological disorders
as well as other manifestations, such as limb amputations and renal and ophthalmic diseases.
The major underlying pathology of most cardiovascular diseases is atherosclerosis3–5—the de-
velopment of plaques in medium-sized vessels, followed by the rupture of these plaques and
thrombosis, which precipitates the tissue ischemia producing the clinical consequences.6,7 The
major drivers of atherosclerosis are cigarette smoking, hypertension, mental status, hyperlipi-
demia, insulin resistance, hyperglycemia, and nonmodifiable factors, such as age and genetics.1
Atherosclerosis in humans commences with a preinflammatory stage involving the trapping
of lipids in the vessel wall by modified proteoglycans,8–10 followed by an inflammatory stage
involving multiple immune cells resulting in the formation of atherosclerotic plaques.4,11 These
plaques can be stable or labile where the latter are vulnerable to rupture and the acute pre-
cipitation of adverse clinical events.6,7 Treatments for atherosclerosis are directed at the above
risk factors most prominently systemically directed treatments, such as antihypertensives and
lipid-lowering medications, but even in clinical trials these strategies only prevent one-third
of the cardiovascular events.12,13 What is required is a greater understanding of the mecha-
nisms of plaque formation and determinants of stability and liability in the vessel wall and
the generation of novel therapeutic agents that address these drivers of the atherosclerotic
process.8,11,14 Among the therapeutic agents tested preclinically, pharmacological inhibitors of
poly(ADP-ribose) polymerase 1 (PARP1, also named as ARTD115) are of therapeutic efficacy
in experimental models of atherosclerosis.16 Therefore, this review focuses on, PARP1, one
such novel potential target, its role in plaque development, and stability and its potential as a
therapeutic target.
2. BRIEF OVERVIEW OF POLY(ADP-RIBOSYL)ATION
Poly(ADP-ribosyl)ation (PARylation), catalyzed by PARPs, is an ancient, reversible posttrans-
lational modification that regulates DNA repair, gene transcription, metabolism, and immune
functions. It was discovered in 1963 by Chambon et al.17 PARylation commences with the
nucleophilic attack of the glycosidic bond between nicotinamide (NAM) and ADP-ribose
(ADPR) portion of NAD+ by positively (e.g., lysine residue18) and negatively (e.g., glutamic
and aspartic acid residues) charged amino acids, or the carboxyl terminus of proteins (Fig. 1).19
ADPR moieties bind to the aforementioned positively and negatively charged groups by form-
ing an ester bond.18,20 Further ADPR units can be joined to the 2′ or 3′ hydroxyl groups of
ribose leading to the formation of large, branched PAR chains on proteins consisting of up to
200 ADPR units.21
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Figure 1. The chemical structure of NAD+ and domain structure of PARP1. (A) PARP1 cleaves NAD+ by
attacking the N-glycosidic bond, thereby releasing nicotinamide (NAM, highlighted in brown) and ADP-ribose.
(B) Schematic representation of human PARP1 domains. The PARP1 protein has multiple functional domains: the
DNA-binding domain (DBD) in the N-terminus including two Zinc-finger motifs (Zn1, Zn2), followed by a nuclear
localization signal (NLS) and Zn3 motif (a dimerization interface); the automodification domain including a breast
cancer suppressor protein 1 domain (BRCT), a WGR domain (named after a conserved Trp-Gly-Arg sequence
motif), and the catalytic PARP domain in the C-terminus followed by a PARP regulatory domain (PRD). NAM,
nicotinamide; PARP, poly(ADP-ribose) polymerase.
The first identified PARP was PARP1 (EC 2.4.2.30)22 followed by the identification of sev-
eral novel enzymes sharing similar catalytic domains to PARP1 in different species constituting
the PARP enzyme family.23,24 PARP1 is a large, multidomain protein, which consists of several
functional domains, three N-terminal zinc-binding domains (Zn1, Zn2, Zn3) containing the
nuclear localization signal (NLS), automodification domain (AD) that bears the major sites of
automodification and contains a BRCT (breast cancer type 1 susceptibility protein (BRCA1)
C-terminal region) motif, WGR domain (conserved residues tryptophan [W], glycine [G], and
arginine [R]), and C-terminal PARP catalytic domain (PARP)25,26 (Fig. 1). PARP1, consid-
ered the prototypical member of PARPs, is activated by breaks in DNA and abnormal DNA
forms.27–29 Activated PARP1 is responsible for 85–90% of total cellular PARP activity,30 and
the rest is mostly covered by PARP2.30,31 A plethora of proteins are PARylated upon the induc-
tion of PARPs.32,33 PARylation of PARP1 is termed auto-PARylation that inhibits the catalytic
activity of PARP1.34,35 PAR degradation, catalyzed mainly by poly (ADPR) glycohydrolase
(PARG), ADP-ribosyl hydrolase-3 (ARH3), and newly identified macrodomain-containing
proteins (including human MacroD1, MacroD2, C6orf130) as terminal ARHs (which cleave
the terminal ADPR attached to glutamic acid residue)26,36,37 (Fig. 2), is a rapid process:
the PAR half-life is estimated to be less than 1 min in cells.38 Due to such a rapid turnover
rate, sustained activation of PARP1 leads to a substantial decrease in cellular NAD+ levels.
Consequently, the attempt to resynthesize NAD+ depletes cellular ATP levels leading to cell
death.39 Besides cell death, PARP1 and PARylation have been linked to several other, partly
overlapping biological functions, including transcription,40 metabolism, DNA repair,41 and
immune functions42 (Fig. 2).
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Figure 2. The regulation and functions of PARP1 activation. DNA strand breaks recruit PARP1. PARP1 binds to
the sites of DNA damage via the DNA-binding domain (DBD) and initiates the poly(ADP-ribosyl)ation (transfer
of ADP-ribose units from intracellular NAD+ to acceptor proteins) of histones, transcription factors, DNA repair
proteins, unidentified substrates, and PARP1 itself, leading to the formation of long and highly branched ADP-
ribose polymers. These negatively charged poly(ADP-ribosyl)ated substrates modulate a wide range of important
cellular processes including single and double strand DNA repair responses, gene transcription, metabolism,
and immune functions. The polymer attached to PARP1 and substrates can be rapidly hydrolyzed by PARG and
ARH3, leaving the terminal ADP-ribose attached to substrates intact. Recently identified macrodomain-containing
proteins are terminal ADP-ribosyl glycohydrolases that can cleave the terminal ADPR attached to glutamic acid
residue, but not lysine residue (by other hydrolases to be identified). The concerted action of these enzymes
removes poly(ADP-ribose) and terminal ADP-ribose from PARylated PARP1, restoring its ability to recognize DNA
strand breaks and initiate a new round of damage repair. Although not shown to simplify the scheme, both PARG
and ARH3 cleave the ribose-ribose bond in the poly(ADP-ribose) polymer, generating monomeric ADP-ribose.
ADPR, ADP-ribose; ARH3, ADP-ribosyl-hydrolase-3; PARG, poly(ADP-ribose) glycohydrolase; PARP, poly(ADP-
ribose) polymerase.
There are several PARP inhibitors available for the modulation of tissular PARP activity.43
Most inhibitors primarily bind to theNAD+-binding pocket on thePARPcatalytic domain,25,44
as such current PARP inhibitors are therefore pan-PARP inhibitors.45 Substituted NAM in-
hibitors, used as early PARP inhibitors, were shown to have unspecific targets.46,47 More potent
inhibitors seem to have less off-target effects, although less data are available on the specificity
of these compounds (specificity of PARP inhibitors and their applicability in atherosclerosis
treatment is detailed at Chapter 5). Considerable research effort has been dedicated to design
selective PARP inhibitors. The best selectivity attained for PARP2 versus PARP1 is 60-fold, or
for PARP1 versus PARP2 is 10-fold, a degree that probably cannot provide adequate selectivity
in cells or in vivo.48 Selective inhibitors could have practical importance in reducing isoform-
specific adverse effects (e.g., the detrimental effects of PARP2 ablation on the pancreas49 could
be avoided by the application of a PARP1-specific inhibitor that protects the pancreas). There
are several clinical trials testing PARP inhibitors (see Chapter 6).
3. THE ROLE OF PARP1 IN ATHEROGENESIS: CLINICAL AND
EXPERIMENTAL EVIDENCE
There is accumulating evidence showing augmented oxidative DNA damage and PARP1
activation in human atherosclerotic plaques50,51 and in experimental animal models of
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Figure 3. The central role of PARP activation in atherosclerotic plaque formation. Proatherogenic insults (such as
oxLDL, 7-KC, Hcy, LSS, LPS, TNF-α) induce PARP1 hyperactivity (PAR accumulation) by oxidative and nitrosative
stress, leading to the following events: (i) redox-sensitive transcription factors (NF-κB, AP-1, etc.) mediated proin-
flammatory response (ICAM-1, VCAM-1, P-selectin, E-selectin, iNOS, MCP-1); (ii) depletion of NAD+ and ATP,
causing cellular energy crisis (necrosis), also the downregulation of atheroprotective SIRT1; (iii) reducing eNOS
activity and increasing the expression of adhesion molecules, leading to endothelial dysfunction; (iv) ACAT-1
mediated foam cell death; (v) caspase-independent activation of parthanatos by triggering mitochondrial release
of AIF and translocation to nucleus. All these events promote the initiation and progression of atherosclerosis.
PARP inhibitors inhibit atherosclerotic plaque formation and enhance plaque stability by inhibiting PARP acti-
vation and PAR accumulation. ACAT-1, acetyl-coenzyme A acetyltransferase-1; AIF, apoptosis inducing factor;
AM, adhesion molecules; AP-1, activator protein-1; eNOS, endothelial NO synthase; Hcy, homocysteine; iNOS,
inducible nitric oxide synthase; LPS, lipopolysaccharide; LSS, low-shear stress; NF-κB, nuclear factor kappa
B; oxLDL, oxidized LDL; PARP, poly(ADP-ribose) polymerase; PAR, poly(ADP-ribose); SIRT1, sirtuin 1; TNF-α,
tumor necrosis factor-α; 7-KC, 7-ketocholesterol.
atherosclerosis.16 Proatherogenic conditions that can produce free radicals and oxidants within
vascular cells, including oxidized low-density lipoprotein (oxLDL),52,53 oxysterols within
oxLDL (such as 7-ketocholesterol [7-KC]),54 immunogenic lipopolysaccharides (LPS),55 ho-
mocysteine (Hcy),56,57 hyperglycemia,58 angiotensin II (Ang-II),59 low-shear stress (LSS),60
myeloperoxidase-derived hypochlorite,61 H2O2,62 and peroxynitrite,63 have been identified as
activators of PARP1. Depending on the severity of DNA damage, three relevant events may
be triggered in atherosclerosis:25,64–66 (i) activation of PARP1 by mild DNA damage is physi-
ologically relevant by promoting DNA repair, which prevents the formation of atherosclerotic
plaques; (ii) more severe DNAdamage induces caspase-dependent apoptosis as well as caspase-
independent cell death (mediated by apoptosis inducing factor [AIF]); (iii) themost severeDNA
damage causes excessive activation of PARP1, which induces the intracellular depletion of its
substrate NAD+ and of the precursor ATP stores, thereby causing a cellular energy crisis
and necrotic cell death65 (PARP activation-coupled cell death has been recently renamed as
parthanatos67). In general, PARP1 participates in the development of atherosclerotic plaques
at multiple steps (Fig. 3).
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A. PARP1 in Inflammatory Conditions
Inflammatory responses are implicated in the pathogenesis of atherosclerosis from initiation
through the phase of progression to ultimate complications.68 The observation that PARP in-
hibitors reduce inflammation was made almost 20 years ago69 and subsequent research efforts
have uncovered multiple molecular processes behind this phenomenon.42 Most knowledge in
conjunctionwith inflammation has been gathered on PARP1, though itmust be noted that there
is also emerging evidence supporting the involvement of other PARPs in inflammatory regula-
tion: PARP2,48,70,71 PARP3,71 tankyrases (PARP5a, PARP5b),72 PARP9,73 and PARP14.74,75
Furthermore, it seems there are PARP enzymes (tankyrases or PARP14) that, in contrast to
PARP1 or PARP2, are anti-inflammatory.72,74,75
PARP1 influences inflammatory processes at multiple levels. The deletion or inhibition
of PARP1 may influence the differentiation and maturation of immune cells, however, ham-
pered cell maturation does not seem to be the determining cause of reduced inflammation in
PARP1−/− mice.42 Specific transcriptional rearrangements provide a plausible explanation for
immunmodulation by PARP1. PARP1 interacts with numerous proinflammatory transcription
factors. The first identified transcription factor was nuclear factor-kappaB (NF-κB)76 followed
by nuclear factor of activated T-cells (NF-AT),77,78 activator protein 1 (AP-1),79–81 Yin Yang 1
(YY1),82 and specificity protein 1 (sp1).83
Genetic or pharmacological deactivation of PARP1 reduces the activation of the above-
mentioned transcription factors that modify gene expression. Analysis of these rearrangements
revealed key processes contributing to the proinflammatory properties of PARP1. In terms
of the inflammatory aspect of atherosclerosis, PARP1 is required for the expression of proin-
flammatory cytokines (IL-1, IL-6, IL-12, TNF-α, MIP-1, MIP-2 [where MIP is macrophage
inflammatory protein]),42 adhesion molecules (intercellular adhesion molecule 1 [ICAM-1],
vascular cell adhesion molecule 1 [VCAM-1], liver cell adhesion molecule [LCAM], etc.),84
inducible nitric oxide synthase (iNOS),85 cyclooxygenase-2 (COX-2),86–88 therefore, deletion or
inhibition of PARP1 results in decreased expression of these proinflammatory mediators via
an inhibitory effect on NF-κB activation.89 Along the same line, PARP1 is also critical in the
assembly of the inflammasome.90 In inflammation, the ratio betweenmatrix metalloproteinases
(MMPs) and their tissue inhibitors (TIMPs) changes in favor of MMPs. PARP inhibition
restores the balance: PARP inhibition, or the deletion of PARP1 restores the appropriate
MMP-9/TIMP-2 ratio.16,80,91,92
The induction of the PARP1-dependent genes (those detailed in the previous paragraph)
support tissue infiltration and activation of immune cells therefore sustaining and enhancing
inflammation, and increasingoxidative stress.Oxidative stress, on the onehand, enhances redox-
sensitive transcription factors (NF-κB, e.g.),93 while on the other, induces PARP-mediated cell
death.39 PARP1 hyperactivation diverts cell fate toward parthanatos.66,67,94 From the perspec-
tive of inflammation, it is important to note that parthanatos leads to cellular disintegration
that aggravates inflammation.65
Available human data indicate that the findings observed in mice seem transferable to
humans.Administrationof a potent PARP inhibitor-INO-1001 showed a tendency to reduce the
level of IL-6 and C reactive protein (CRP), suggesting that INO-1001 is capable of reducing the
expression of inflammatory mediators in patients.95 However, it must be noted that functional
redundancy among PARPs (e.g., PARP1 vs. PARP296,97) may lead to the underestimation of
the role of PARP1 in inflammatory processes and in particular in atherosclerosis.
B. PARP1 and SIRT1
Sirtuins (SIRTs) were identified as essential regulators of metabolism.98–101 Yeast Sir2 protein,
the prototypical enzyme of the family was identified decades ago,102,103 however, true interest in
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these enzymes arose when Imai et al. identified Sir2 as an NAD+ dependent deacetylase.104 In
the course of the deacetylation reaction, Sir2 cleaves NAD+ and acetyl groups are transferred
onto the ADPR moiety of NAD+.104 In mammals the SIRT family constitutes seven members
(SIRT1–7), our review focuses on SIRT1 (for detailed information on SIRTs refer to recent
reviews98,99,105).
Several signal transduction pathways converge on SIRT1, however, the most intriguing
feature for controlling SIRT1 activity relies on its NAD+-dependence. The Km value of SIRT1
(100–300 μM) is close to the normal cellular NAD+ concentration (200–500 μM)106 strongly
suggesting that fluctuations in the cellular NAD+ regulate SIRT1 activity (the understand-
ing of SIRT1 regulation through NAD+ is still incomplete, we refer the reader to specific
reviews106–108 for details). Cellular NAD+/NADH ratio reflects cellular metabolism, whereby
higher levels of NAD+ indicate insufficient energy production. Higher NAD+ levels induce
SIRT1 that through deacetylating certain transcription factors (e.g., peroxisome proliferator
activated receptor-γ coactivator-1α [PGC-1α], forkhead box O1 [FOXO1], p53, sterol regu-
latory element-binding proteins [SREBPs]) alters gene expression (for comprehensive review
on SIRT1 targets see107,109). Altered gene expression fine-tunes mitochondrial activity, glucose
and lipid metabolism to meet the needs of the organism.107,110 SIRT1 activation seems to be
beneficial in metabolic, cardiovascular, and neurodegenerative pathologies, cancer, aging, and
inflammation.105
The NAD+-dependence of SIRT1 is further strengthened by the observation that physio-
logical processes involving energy stress (exercise, fasting, caloric restriction, etc.) elevateNAD+
levels and induce SIRT1 activity.111,112 Furthermore, NAD+ precursors (e.g., NAM-riboside,
or NAM) or increased NAD+ salvage (e.g., NAM phosphoribosyltransferase [NAMPT] over-
expression) enhance SIRT1 activity.108,113,114 Importantly, SIRT1 activity can be also induced
by inhibiting NAD+ degradation (e.g., CD38,115 or PARPs).49,116–118
The idea that SIRT1 and PARP1 may compete for the common NAD+ substrate arose
10 years ago;118 however, it must be noted that the interconnection between SIRT1 and PARP1
is more intricate (for detailed review see108). When comparing the enzymatic properties of
PARP1 and SIRT1, it is evident that PARP1 has a higher affinity for NAD+ compared to
SIRT1 (Km 20–60 μM vs. 100–300 μM, respectively).106,119,120 Furthermore, PARP1 has
a higher catalytic turnover rate than SIRT1.117 Both PARP1 and SIRT1 are present in the
nuclear compartment, therefore may compete for nuclear NAD+, whereby PARP1 can easily
limit NAD+ availability for SIRT1 as evidenced by PARP1 deletion studies.60,116,121–125 SIRT1
does not reciprocally limit NAD+ for PARP1, but deacetylates and inactivates PARP1.125
To date PARylation of SIRT1 has not been detected.116 Other PARPs, such as PARP2 and
PARP7, were also shown to influence SIRT1.49,108,126
The balance between PARP1 and SIRT1 has been shown to modulate several physiological
and pathophysiological processes, such as oxidative stress-mediated pathologies, metabolism,
genomic stability, and aging (detailed review in108), however, it is very likely that the extent of
such processes will increase (e.g., inflammatory diseases) as there is a large overlap between
SIRT1- and PARP1-mediated pathologies that likely involves atherosclerosis.65,100,127,128
Importantly, a recent study showed that SIRT1 activation in smooth muscle cells (SMCs)
is a crucial protective factor against atherosclerosis.129 The ablation or inhibition of PARP1
is antiatherogenic16,130 similarly to SIRT1 activation,129 therefore, it is likely that the interplay
between SIRT1 and PARP1 could have prime importance in atherosclerosis. There are several
key points where disturbances in the balance between SIRT1 and PARP1 may hypothetically
contribute to atherosclerosis. (i) Enhanced PARP1 activation may lead to the inhibition of
SIRT1 hampering feeding behavior131 and nutrient storage108,116 in a proatherogenic fash-
ion. (ii) PARP1 activation is proinflammatory42,132–135 and therefore proatherogenic, while
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SIRT1 opposes inflammation,136 therefore, it is likely that the balance of the two proteins sets
the inflammatory tone. Furthermore, it has been recently demonstrated that the joint action
of SIRT1 and PARP1 is required for the appropriate functioning of NF-κB,137 which is a
proatherogenic transcription factor. (iii) Cholesterol homeostasis might be influenced by the
PARP1-SIRT1 balance as SIRT1 activation reduces SREBP activity,109,138 while the inhibition
or genetic deletion of PARP1 has beneficial effects on the HDL/LDL ratio.139 (iv) PARP1
and SIRT1 regulate each other’s activity in vascular oxidative stress-mediated events108,125 and
atherosclerosis is characterized by oxidative stress. (v) In aging, a risk factor for atheroscle-
rosis, PARP1-SIRT1, activities are unbalanced.140–143 (vi) PARP enzymes, other than PARP1,
also interact with SIRT1108 and regulate proatherogenic processes (e.g., inflammation or fat
storage).42,48,108,144 It should be stressed that these points connecting PARP1–SIRT1 balance
to different risk factors of atherosclerosis are speculative and warrant further investigation.
C. PARP1 and Endothelial Dysfunction
Endothelial dysfunction, in which the barrier and signal-transduction function of endothelial
cells (ECs) are impaired, is a hallmark of early atherosclerosis.145 The activation of ECs leads
to increased expression of proinflammatory cytokines and adhesion molecules (including E-
selectin, P-selectin, VCAM-1, ICAM-1) that promote leukocyte adhesion, and transmigration
into the inflamed subendothelium.145 These cellular processes are fundamental to initiation,
progression, and destabilization of atherosclerotic plaques.145
Recent evidence suggests that PARP1 is involved in the endothelial dysfunction observed in
various pathophysiological conditions, such as atherosclerosis,62 ischemia reperfusion injury,146
hypertension,147 diabetes,58 chronic heart failure,148 and aging.149,150 An important milestone
in establishing the critical role of PARPs in endothelial dysfunction stems from two reports
from Szabo’s laboratory.130,151 These investigators showed that the activation of PARP1 con-
tributes to the development of endothelial dysfunction in peroxynitrite-induced cytotoxicity
of human ECs as well as in a rat model of endotoxemia. Also, pharmacological inhibition of
PARP by INO-1001 restores the endothelium-dependent vasorelaxant responses in the aor-
tic rings of ApoE−/− mice fed with a high-fat diet (HFD).151 Long-term pharmacological
inhibition of PARP (by PJ-34) or genetic deletion of PARP1 inhibits atherosclerotic plaque
formation in ApoE−/− mice by decreasing the expression of adhesion molecules (such as
VCAM-1, P-selectin, and E-selectin).133 In cultured ECs, pharmacological inhibition of PARP
by 3-aminobenzamide (3-AB) reduces peroxynitrite induced P-selectin expression and TNF-α
induced ICAM-1 expression.146 Moreover, lymphocyte adhesion to a monolayer of TNF-α-
activated ECs was higher in PARP1+/+ than PARP1−/− ECs,152 suggesting that PARP1 is a
critical determinant of the expression of adhesion molecules in vivo and in vitro.
PARP1 also mediates vasorelaxation as long-term treatment with the PARP inhibitor
PJ-34 or INO-1001 significantly improves endothelium-dependent relaxation, suggesting the
involvement of free radical production-induced PARP activation in the pathogenesis of
atherosclerosis.149 The burst of reactive oxygen species (ROS) including H2O2, superoxide
anion (•O2−), and hydroxyl radical (•HO; generated by mitochondria, NADPH oxidases, xan-
thine oxidase, uncoupled endothelial NO synthase [eNOS] activity, as well as exposure to
inflammatory cytokines and growth factors), is another important factor causing endothelial
dysfunction.145,153 Superoxide interacts with vasodilatory nitric oxide (NO) in a rapid and
diffusion-controlled manner to form the oxidant peroxynitrite (ONOO−) that can cross cell
membranes, enter the nucleus, and trigger breakage in the strands of DNA.154 DNA break-
age triggers PARP1 activation, resulting in rapid depletion of the intracellular NAD+ and
ATP levels, contributing to sustained endothelial dysfunction and inflammation.153,155 The
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most probable explanation for PARP1-induced endothelial dysfunction is a reduction in the
phosphorylation of eNOS and therefore suppressed NO bioavailability. eNOS is an NADPH-
dependent enzyme156 andGarcia Soriano et al.58 suggested that PARP1mediates eNOS activity
through depleting and hence limitingNADPH inECs exposed to high glucose. There is also evi-
dence showing that phospho-eNOS immunoreactivity (the phosphorylation site is not specified
by the authors) is significantly enhanced in ApoE−/− PARP1−/− mice compared to ApoE−/−
mice, following either normal diet or HFD, without affecting total eNOS mRNA and protein
expression.139 Although the effect of PARP1 activation on endothelial dysfunction is well recog-
nized, the effect of PARP1 on oxLDL uptake by ECs (mainly via lectin-like oxLDL receptor 1
[LOX-1]) remains incompletely understood. This aspect needs to be examined in further studies.
D. PARP1, Foam Cell Formation, and Foam Cell Death
PARP1 activation caused by proatherogenic stimuli can induce nuclear translocation of NF-κB
and subsequent upregulation of inflammatory mediators, including ICAM-1, VCAM-1, and
monocyte chemoattractant protein 1 (MCP-1).157 These events drive the recruitment and ad-
hesion of monocytes to the diseased endothelium and their differentiation into macrophages,
being a prerequisite step for macrophages to become lipid-laden foam cells. Multiple scavenger
receptors (SR; such as SR-A, CD36, and LOX-1)158 and transporters (such as ATP-binding
cassette transporter [ABC] A-1, ABCG-1, and SR-BI) are involved in the uptake and efflux
of oxLDL and subsequent foam cell formation. PARP1 deletion does not affect fluorescently
labeled acetyl-LDL (ac-LDL) uptake in foam cells.159 In agreement with this finding, PARP in-
hibition by thieno[2,3-c]isoquinolin-5-one (TIQ-A) had no significant impact on the expression
of ABCA-1 or SR-A, but it markedly reduced acetyl-coenzymeA acetyltransferase 1 (ACAT-1)
expression in atherosclerotic lesions of ApoE−/− mice and in macrophage foam cells treated
with ac-LDL or 7-KC (the main oxysterol in oxLDL).160 These data may suggest that TIQ-A
does not affect cholesterol influx (by SR-A) and efflux (byABCA-1) processes.160 More recently,
it has been reported that PARP1 activation promotes NF-κB transcriptional activity by reduc-
ing NAD+ concentrations and thereby inhibiting SIRT1-mediated deacetylation of NF-κB p65
subunit.161 As LOX-1 is transcriptionally regulated by NF-κB, it is plausible that PARP1 acti-
vation may aggravate atherosclerosis by enhancing LOX-1-mediated macrophage-derived foam
cell formation.162 More experiments are undoubtedly required to clarify the effect of PARP
inhibition (by genetic deletion or pharmacological agents) on oxLDL uptake and Apo-AI- or
HDL-mediated cholesterol efflux in quantitative assays.
PARP1 also contributes to foam cell death, which is an important determinant of plaque
composition. In ex vivo–generated foam cells (stimulated with ac-LDL), PARP inhibition was
highly protective against 25μMH2O2-induced cytotoxicity. At a higher concentration of H2O2
(50 μM), PARP1 knockout not only protected against H2O2-induced cytotoxicity, but also
switched necrotic cell death to apoptosis as assessed by AnnexinV-PI staining.16 In a following
study, Hans et al.159 demonstrated that pharmacological inhibition of PARP protects against
the death of vascular cells in response to inflammatory factors, including 7-KC. These data
coincide with the fact that PARP inhibition diverts necrosis to apoptosis,66,94 thereby reducing
the likelihood of enlarged necrotic core formation, which may be of therapeutic benefit in
stabilizing vulnerable plaques.
E. PARP Inhibition and Lipid Levels
The majority of atherosclerotic patients have elevated circulating cholesterol levels, which can
be addressed therapeutically by cholesterol-lowering drugs, such as statins. Therefore, it is
important to know whether PARP inhibition exerts its effects by altering the lipid profile.
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In ApoE−/− mice, a strain susceptible to atherosclerosis, 16 weeks of HFD regimen dra-
matically increased total cholesterol (TC) and LDL-cholesterol (LDL-C) levels. The high fat
regimen-induced elevation in TC and LDL-C was less pronounced in ApoE−/−PARP1−/−
mice. The atherogenic index (Log [triglycerides/HDL-C]) was significantly higher in ApoE−/−
mice than in ApoE−/−PARP1−/− mice on normal diet as well as on HFD.139 Similarly, in
another study of ApoE−/− mice with preexisting atherosclerotic plaques, TIQ-Amarkedly low-
ered serum LDL-C levels, compared with vehicle-treated mice,160 suggesting that the protective
and regressive effects of PARP1 inhibitors may be mediated partly through reduction of lipid
levels. It is also observed that treatment of 10-week-old mice with PJ-34 (10 mg/kg) for 5 days
can also reduce serum triglyceride and free fatty acid levels, potentially via activation of the
NAD+-SIRT1-oxidative metabolism pathway.116 In contrast, there are other studies reporting
that PARP1 inhibition or deletion has no significant effect on lipid profile.16,163 These discrep-
ancies may arise from different experimental settings, the choice of PARP inhibitor, genetic
background of the animals, the duration of treatment, as well as the type of atherogenic diet.117
It will be of more clinical relevance to examine whether PARP inhibition alters lipid levels in
hyperlipidemic human subjects.
4. THE ROLE OF PARP1 IN PLAQUE DESTABILIZATION
Disruption of unstable atherosclerotic plaques (‘‘vulnerable’’ plaques) and subsequent
formation of occlusive thrombi are the primary causes of acute coronary syndrome (ACS).164
The so-called ‘‘vulnerable’’ plaques are characterized by large necrotic cores, thin fibrous caps
(caused by SMCs apoptosis and matrix degradation), enhanced inflammatory state, advanced
lesional macrophage apoptosis, together with defective efferocytosis (phagocytic clearance of
apoptotic cells).165,166 Activated PARP1 is present in circulating mononuclear cells of patients
with unstable angina, concurrent with NF-κB activation and increased expression of TNF-α
and IL-6.167 PARP inhibitors facilitate foam cell death, but protect against the death of SMCs
and ECs, which is favorable for enhancing plaque stability and regression.159 This finding
suggests that PARP inhibition confers a prosurvival, a neutral, or a prodeath effect in the
plaque dynamics dependent on the vascular cell types (macrophage foam cells, ECs, or SMCs)
and type and duration of proatherogenic stimuli (7-KC, H2O2, or TNF-α). The molecular
mechanisms by which PARP inhibitors or PARP1 genetic deletion stimulate the death of
foam cells are not fully characterized. ACAT-1 is the principal enzyme that converts cytotoxic
free cholesterol to esterified cholesterol in macrophage foam cells, thereby contributing to the
lowering of cytotoxicity.168 Genetic deletion of PARP1 or treatment with the PARP inhibitor
TIQ-A in ApoE−/− mice downregulates ACAT-1 mRNA and protein expression in vivo and
in 7-KC-treated macrophage foam cells. This observation suggests that PARP1 inhibitors may
promote free cholesterol-mediated cell death by inhibiting ACAT-1 expression.159 Moreover,
PARP1 gene deletion significantly reduces prodeath caspase-3 and c-Jun N-terminal kinase
(JNK) activation in SMCs stimulated with TNF-α or 7-KC, and also induces the prosurvival
extracellular signal-regulated kinases (ERKs) signaling pathway, resulting in the net decrease of
SMC apoptosis. This effect might contribute to the reversal of the thinning of the fibrous cap in
vulnerable plaques.159 TIQ-A treatment also resulted in a significant decrease in nitrotyrosine
and 8-oxo-2′-deoxyguanosine (8-oxo-dG) immunoreactivity, suggesting that PARP inhibitors
promote plaque stability by modulating nitrosative stress and oxidative stress.159 In addition,
in the plaques of ApoE−/− mice receiving TIQ-A treatment or those that are heterogeneous
for PARP1, SMCs and collagen content was increased, fibrous caps were thicker, and lipid
cores were well contained. These protective effects result from increased expression of TIMP-2
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Figure 4. The chemical structures of PARP inhibitors with demonstrated antiatherosclerotic effects. Nicotinamide
(NAM), which is released in the poly(ADP-ribosyl)ation process, was the first PARP inhibitor identified. All of the
current classes of PARP inhibitors are based on the NAM/benzamide pharmacophore. PARP, poly(ADP-ribose)
polymerase.
and TIMP-3, without a significant effect on collagen I mRNA expression.16,160 Moreover,
in ApoE−/− mice kept on a high cholesterol diet, treatment with the PARP inhibitor PJ-34
increased the thickness of the fibrous cap and collagen content, while reducing the necrotic
core diameter and apoptotic cell death, thus, favoring features of plaque stability. However,
PJ-34 did not affect cell proliferation.133 These data suggest that PARP1 is critically involved
in plaque destabilization by modulating plaque composition, which can be prevented by PARP
inhibitors.
The ratio of MMPs to TIMPs is another important determinant of plaque instability.
Genetic ablation of PARP1 or pharmacological inhibition of PARP by PJ-34 also restores the
original MMP-9/TIMP-2 ratio in oxazolone-induced contact hypersensitivity in mice80,92 and
an apparently similar rebalancing may be induced by PARP inhibitors in atherosclerosis as
shown by Oumouna-Benachour et al.16 All these data underscore the potential involvement of
PARP1 in plaque instability. It remains to be determined, however, whether PARP inhibition
exerts antiatherosclerotic effects by promoting efferocytosis, a process that clears apoptotic cells.
Despite consistent reports on the inhibitory effects of PARP inhibitors on lesion progression,
reports on the plaque-stabilizing effects of PARP inhibitors are inconsistent.163 For example,
Erbel et al.163 recently observed no difference in collagen and SMC content between vehicle
and INO-1001-treated ApoE−/− mice. These contradictory reports might be explained by
differences in PARP inhibitors, mouse strains, as well as the type of atherogenic diet.
5. PARP INHIBITORS AS ANTI-ATHEROSCLEROTIC AGENTS
Based on the structure of NAM/benzamide, several PARP inhibitors, including 3-AB,57,157,169
PJ-34,58,133,170 TIQ-A,16,160 ABT-888 (Veliparib),60 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-
1(2H)-isoquinolinone (DPQ),52,53,171,172 INO-1001,59,62,163,173,174 and the tetracycline derivates
minocycline175,176 and doxycycline168,177,178 demonstrate atheroprotective effects by decreasing
PARP activation, inflammatory markers, macrophage recruitment, endothelial dysfunction,
foam cell death, and by promoting plaque stability. The chemical structures of these inhibitors
show that they share theNAM/benzamide pharmacophore (Fig. 4). However, it is important to
note that these PARP inhibitors may not only inhibit members of the PARP family,45 but also,
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presumably at higher concentrations, inhibit other completely unrelated targets, such as PJ-34
that inhibits Pim kinases179 and 3-AB that inhibits the generation of oxidant species180 and
MMP-2 activity.181 However, the fact that PARP1 knockout animals are also protected against
atherosclerosis suggests that the antiatherogenic activity of PARP inhibitors is indeed related to
the inhibitionof PARP1.ThePARP inhibitors used in the experimental and clinical therapeutics
for atherosclerosis are summarized in Table I and II. However, it remains elusive whether other
PARP inhibitors in clinical development will reduce plaque burden in experimental animals
and patients with ACS.
A. 3-AB
3-AB is a prototypical PARP inhibitor that has been used in multiple studies.65 A recent study
has shown that 3-AB substantially reduced atherosclerotic plaque area (by 40%) inHcy-induced
atherosclerosis, but it has no significant effect on plaque area from chow-diet fedApoE−/− mice.
Interestingly, the plasma Hcy level and lipid contents are not affected by 3-AB.157 The athero-
protective effect afforded by the 3-AB was due to an inhibitory effect on PARP activation, and
inhibitory effects on NF-κB-mediated production of inflammatory factors, such as VCAM-1
andMCP-1.157 In a ratmodel of hyperhomocysteinemia, 3-AB improves acetylcholine-induced,
NO-mediated vasodilation by decreasing the levels of nitrite/nitrate and endothelin-1. These
findings indicate that 3-AB may be helpful in preventing endothelial dysfunction in the setting
of hyperhomocysteinemia.57 In isolated rat aortic arteries stimulated with Hcy, 3-AB not only
prevents, but also reverses Hcy-induced endothelial dysfunction.56 3-AB (10 mg/kg, i.v.) also
attenuates myocardial ischemia/reperfusion injury in rats by decreasing the activity of creatine
phosphokinase and myeloperoxidase, peroxynitrite-induced cytotoxicity, and by preserving
myocardial ATP levels in the infarcted hearts.182 In parallel, in cultured ECs, 3-AB decreases
peroxynitrite-induced P-selectin expression and TNF-α-induced ICAM-1 expression.146 Al-
though 3-AB has served as the “benchmark” inhibitor of PARP for a long time, one must bear
in mind that this compound has additional, non-PARP-related pharmacological effects, such
as antioxidant and MMP-2 inhibitory activities, and therefore, some of the protective effects
observed with 3-AB may be mediated by direct oxidant scavenging and MMP-2 inhibition,
rather than direct catalytic inhibition of PARP activation.65,180,181 Therefore, it is advisable to
confirm the atheroprotective effects of 3-AB by using more potent and specific PARP inhibitors
(see below) and/or PARP1 deficient cells or animals.
B. TIQ-A
TIQ-A reduces plaque burden in ApoE−/− mice fed with aHFDwithout affecting lipid levels.16
These findings are corroborated genetically with the use of ApoE−/− mice that are heterozygous
for PARP1.133 TIQ-A also promotes an increase in collagen content, potentially through an
increase in TIMP-2, and transmigration of SMCs to the intima of atherosclerotic plaques.16 In
a subsequent study with preestablished atherosclerotic plaques in ApoE−/− mice, TIQ-A, ad-
ministered with a normal chow diet, promoted the regression of established plaques, concurrent
with a reduction inTCandLDL-C.Furthermore, increased collagen and SMCcontent together
with decreased macrophage content, and thicker fibrous caps were observed in atherosclerotic
plaques of TIQ-A-treatedmice, suggesting enhanced plaque stability.160 These changes are asso-
ciated with diminished expression ofMCP-1, ICAM-1, TNF-α, as well as ACAT-1, rather than
ABCA-1 and SR-A.159,160 However, the effect of TIQ-A on CD36-mediated oxLDL uptake
and HDL-mediated macrophage cholesterol efflux was not quantitatively analyzed.
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Table I. Beneficial Effects of PARP Inhibition/Deletion in Animal Models of Atherosclerotic Cardio-
vascular Diseases
Mode of PARP
inhibition Disease model/patients Effect of PARP inhibition References
3-AB 1. ApoE−/− mice + Hcy
2. Rats fed with a
high-methionine diet
3. Myocardial I/R in rats
↓AIF nuclear translocation,
↑vasorelaxation
–Hcy, –lipid profile, ↓NF-κB,
↓VCAM-1, ↓MCP-1
↓Infarct size,
↑endothelium-dependent vascular
relaxation
↓Serum creatine phosphokinase,
↓MPO activity ↓neutrophil
infiltration, ↓nitrotyrosine, ↑ ATP
↓MDA, ↑NO, ↓ET-1
57,157,182
TIQ-A ApoE−/− mice + HFD ↓Plaque number and size, –serum
lipid profile
↑SMCs and collagen content,
↑TIMP-2
↑SMCs migration to intima
↓NF-κB DNA binding activity,
↓MCP-1, ↓ICAM-1, ↓TNF-α
↓nitrotyrosine, ↓8-oxo-dG
↓Foam cell death, ↓macrophage
recruitment
↓TC, ↓VLDL-C+LDL-C
–ABCA-1, –SR-A, ↓ACAT-1,
↓caspase-3
16,159,160
PJ-34 1. ApoE−/− mice +
HCD
2. Streptozotocin-
induced diabetic
mice
3. Ang-II-infused rats
4. Isolated rat aortic
rings
5. Balloon-injured rat
carotid artery
↓Plaque area, ↓apoptosis,
-proliferation
↓E- and P-selectin, ↓VCAM-1,
↓iNOS
↓Macrophage and T cell content,
↑fibrous cap thickness
↓Necrotic core area, ↑collagen
content
↑Endothelium-dependent relaxation
–plasma glucose, –TC, ↑endothelial
dysfunction
↑ATP, ↑NAD+, ↑NADPH,
↓neointima formation
↓CD45+ leukocyte infiltration,
↑endothelial cell recovery
↑Ach-stimulated cGMP content
59,133,183,184
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Table I. Continued
Mode of PARP
inhibition Disease model/patients Effect of PARP inhibition References
ABT-888 Diabetic db−/db− mice ↓Myogenic tone,
↑Endothelium-dependent
relaxation
↑p-eNOS, ↑cGMP, ↑cleaved
PARP1
147
DPQ Myocardial I/R in rats ↓Myocardial infarct size, ↑cardiac
function
↓TUNEL+ apoptotic cells,
↓p-JNK
↓AIF translocation from
mitochondria to nucleus
↓NF-κB DNA binding activity,
↓ICAM-1, ↓COX-2, ↓MMP-9,
↑p-Akt, ↑p-GSK-3β,
↑p-FOXO3a
52,171
INO-1001 1. ApoE−/− mice + HFD
2. Carotid endarterectomy
in rats
3. Patients with
ST-elevation myocardial
infarction
–Lipid profile, ↓dendritic cells, ↓T
lymphocytes ↓macrophages,
↓oxLDL auto-antibody,
–collagen content ↓apoptosis,
–SMCs content, ↓MIP-3α,
↓CD83, ↓IL-12 ↓iNOS,
↓VCAM-1, ↓caspase-3
↑Endothelium-dependent
relaxation
↓Neointima formation,
↓neutrophil infiltration
↓AIF nuclear translocation,
↓nitrotyrosine
Trend toward blunted CRP, IL-6
95,130,163,186
Minocycline 1. ApoE−/− mice + HFD
2. New Zealand white
rabbits + HCD
↓Lesion size and stenosis, ↓SMCs
proliferation, ↓p27Kip1
↓Macrophage content, ↓ MMP-2,
↓ MMP-9 activities
168,175
Doxycycline 1. ApoE−/− mice + chow
diet
2. Patients with ACS
3. Ang-II infused
LDL-R−/−mice
4. Balloon catheter
denudation of rat carotid
artery
–TC, –TG, ↓lesion size, ↓CRP,
↓IL-6, ↓MMP-9, ↑HDL
↓TNF-α, ↓MCP-1, ↓p-NF-κB
–Systolic blood pressure
↓Ang-II-Induced AAAs incidence
and severity
–Ang-II-Induced atherosclerosis
↓MMP-2, ↓MMP-9 activity,
↓Intima/media ratio
↓SMCs migration and
proliferation
189–192
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Table I. Continued
Mode of PARP
inhibition Disease model/patients Effect of PARP inhibition References
PARP1−/− 1. ApoE−/− mice +
HFD
2. Myocardial I/R in
mice
↓TC, ↓LDL-C, ↓atherogenic index,
–heart rate
↑Baroreflex sensitivity, ↓p-eNOS,
↓iNOS, ↓nitrotyrosine, ↓dilated
cardiomyopathy
↓MMP-9 activity, ↑TIMP-2 and
TIMP-3 expression
↓Serum creatine phosphokinase
↓MPO activity, ↓neutrophil
infiltration
↓Nitrotyrosine, ↓P-selectin,
↓ICAM-1
↓Disruption of the myocardial
structure
91,139,146
AAAs, abdominal aortic aneurysms; ABCA-1, ATP-binding cassette transporter-1; ACAT-1, acetyl-
coA cholesterol acyltransferase-1; Ach, acetylcholine; ac-LDL, acetyl-LDL; ACS, acute coronary
syndrome; AIF, apoptosis inducing factor; Ang-II, angiotensin-II; ApoE−/−, apolipoprotein E knock-
out; CE, cholesterol ester; cGMP, cyclic guanosine monophosphate; COX-2, cyclooxygenase-
2; CRP, C reactive protein; DPQ, 3,4-dihydro-5-[4-(1-piperidinyl)butoxyl]-1 (2H)-isoquinolinone;
ET-1, endothelin-1; FC, free cholesterol; FOXO-3a, forkhead box O-3a; GSK-3, glycogen syn-
thase kinase-3; Hcy, homocysteine; HCD, high-cholesterol diet; HDL-C, high-density lipoprotein-
cholesterol; HFD, high-fat diet; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; iNOS,
inducible nitric oxide synthase; I/R, ischemia/reperfusion; LDL-C, low-density lipoprotein; LDL-R,
LDL receptor; LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; MDA, mal-
ondialdehyde; MIP-3, macrophage inflammatory protein-3; MMP-9, matrix metalloproteinase-9;
MPO, myeloperoxidase; p-JNK, phosphorylated c-Jun NH2-terminal kinase; p-NF-B, phospho-
rylated nuclear factor kappa B; oxLDL, oxidized LDL; PAR, poly(ADP-ribose); PARP1, poly(ADP-
ribose) polymerase 1; p-eNOS, phosphorylated endothelial nitric oxide synthase; SIRT1, sirtuin 1;
SMCs, smooth muscle cells; SR-A, scavenger receptor-A; TC, total cholesterol; TG, triglyceride;
TIMP, tissue inhibitor of metalloproteinases; TIQ-A, thieno[2,3-c]isoquinolin-5-one; TUNEL, terminal
deoxynucleotidyl transferase dUTP nick end labeling; VCAM-1, vascular cell adhesion molecule-1;
VLDL-C, very-low density lipoprotein; 3-AB, 3-aminobenzamide; 7-KC, 7-ketocholesterol; 8-oxo-dG,
8-oxo-2′-deoxyguanosine; ↓ denotes “decrease”, ↑ denotes “increase”, – denotes “no significant
effect.”
C. DPQ
DPQ is a highly potent and selective inhibitor of PARP1. It was demonstrated that DPQ in-
hibits PARP activation in oxLDL-stimulated human aortic ECs in vitro and in myocardial
ischemia–reperfusion injury.53 PARP inhibition by DPQ partially restored aldehyde dehydro-
genase 2 (ALDH2) activity in oxLDL treated human aortic ECs and ischemia–reperfusion rat
hearts by preventing SIRT3-mediated deacetylation.53 These data suggest that DPQ may be of
great benefit in the therapy of atherosclerosis by promoting ALDH2-catalyzed metabolism of
aldehydes (into less reactive chemical species), the major end products of lipid peroxidation.
DPQ also reduces heart ischemia/reperfusion injury by suppressing the PARP1/JNK/AIF
pathway.52 More recently, the same group showed that DPQ protects against oxLDL-induced
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Table II. Atheroprotection Conferred by PARP Inhibition/Deletion in vitro
Mode of PARP
inhibition Stimuli Target cell Effect of PARP inhibition References
3-AB TNF-α,
Peroxynitrite,
TGF-β1
1. ECs,
2. SMCs
↓P-selectin, ↓ICAM-1,
↑mitochondrial
respiration
↓Peroxynitrite induced
cytotoxicity
↓p-Smad3, ↓PARylation
and DNA binding of
Smad3
↓Collagen Iα1, ↓collagen
IIIα1, ↓TIMP-1
146,169,182
TIQ-A 7-KC Foam cells –ABCA-1, –SR-A,
↓ACAT-1,
↑H2O2-induced
apoptosis
↓Necrosis, –ac-LDL uptake,
↑Sensitization to 7-KC
↑TC, ↑FC, ↓CE,
↓Caspase-3 activation
159,160
PJ-34 LPS 1. SMCs
2. Macrophages
↓PARP1, ↓p27Kip1,
↓MIP-1α, MIP-2
↓NF-κB DNA binding and
transcriptional activity,
–MAPK
168,170
ABT-888 Low-shear stress,
High glucose
ECs ↑NAD, ↑SIRT1 activity,
↓p-NF-κB
↓NF-κB nuclear
translocation and DNA
binding activity
↓iNOS, ↓ICAM-1, ↓O2.−,
↓nitrotyrosine, ↓
p-H2A.X
↓cleaved PARP1,
↓DNA-binding activity
of PARP1, ↓DNA tails
60,147
DPQ oxLDL ECs ↑ALDH2 activity, ↓cellular
NAD+, –mt NAD+,
↓SIRT3
↑cell viability, ↓PARP1,
↓iNOS, ↓nitrotyrosine,
↓NO
↓TUNEL+ apoptotic cells
172
INO-1001 Hypoxia and
reoxygenation,
TNF-α
1. Macrophages
2. ECs
↓TNF-α, ↓MIP-1α,
↓NF-κB expression
↓NF-κB nuclear
translocation, ↓ICAM-1
173,174
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Table II. Continued
Mode of PARP
inhibition Stimuli Target cell Effect of PARP inhibition References
Minocycline LDL,
Chlamydia
pneumoniae
infection
1. SMCs
2. C. pneumonia
infected human
monocytes
↓ Proliferation, –migration,
–Apoptosis
↓PARP1, ↓p27Kip1
↓Monocytes differentiation to
macrophages
↓Phagocytic activity
168,176
Doxycycline CRP/oxLDL,
LPS
PBMCs ↓TNF-α, ↓IL-6, ↓MCP-1,
↓CRP, ↓MMP-9, ↓p-NF-κB
↑apoA-I, ↑HDL-C
178
PARP1−/− LPS 1. SMCs and ECs
2. Macrophages
↓p-NF-κB, ↓NF-κB nuclear
Translocation
↓NF-κB DNA binding and
transcriptional activity
↓iNOS, ↓ICAM-1, ↑TIMP-2,
↑TIMP-3, ↓MIP-1α and
MIP-2
↓NF-κB DNA binding and
transcriptional activity,
–MAPK
89,91
PARP2−/− DOX SMCs ↑SIRT1, ↑ mitochondrial
biogenesis, –PARP activity,
↑ DOX- induced O2−,
–apoptosis, –NAD+
depletion
31
ABCA-1, ATP-binding cassette transporter-1; ACAT-1, acetyl-coA cholesterol acyltransferase-1; ac-
LDL, acetyl-LDL; ALDH2, aldehyde dehydrogenase 2; ApoA-I, apolipoprotein A-I; CE, cholesterol
ester; DOX, doxorubicin; ECs, endothelial cells; FC, free cholesterol; ICAM-1, intracellular adhesion
molecule-1; iNOS, inducible nitric oxide synthase; LDL, low-density lipoprotein; LPS, lipopolysac-
charide; MAPK, mitogen-activated protein kinase; MIP, macrophage inflammatory protein; MMP,
matrix metalloproteinase; mt NAD+, mitochondrial NAD+; oxLDL, oxidized LDL; PAR, poly(ADP-
ribose); p-H2A.X, phosphorylated histone H2A.X; p- NF-B, phosphorylated nuclear factor-kappa
B; PARP, poly(ADP-ribose) polymerase; PBMCs, peripheral blood mononuclear cells; SIRT1, sirtuin
1; SMCs, smooth muscle cells; SR-A, scavenger receptor-A; TC, total cholesterol; TGF-1, trans-
forming growth factor- 1; TIMP, tissue inhibitor of metalloproteinases; TNF-, tumor necrosis factor-
; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; 7-KC, 7-ketocholesterol.
↓ denotes “decrease”, ↑ denotes “increase”, – denotes “no significant effect.”
apoptosis in microvascular ECs by inactivating the PARP1/iNOS/NO pathway that led to
inhibition of peroxynitrite (nitrotyrosine) formation.172
D. PJ-34
Hcy and high glucose, two independent risk factors for patients with atherosclerosis, trigger
the production of ROS, causing DNA strand breaks and impairing endothelium-dependent
relaxation. Pharmacological PARP inhibition by PJ-34 not only prevents, but also rapidly
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reverses the development of endothelial dysfunction under diabetic conditions183 and in
hyperhomocysteinemia.56 In ApoE−/− mice fed with a high-cholesterol diet, treatment with
PJ-34 decreased atherosclerotic plaque formation by 46% via diminishing the expression level
of adhesion molecules.133 Furthermore, PJ-34 reduces the content of macrophages and T-cells,
while increasing the thickness of the fibrous cap, favoring features of plaque stability.133 PJ-34
was also able to suppress the pathogenesis of chronic heart failure,148 aging,148 and neointima
formation after balloon injury.184 However, recent studies have shown that PJ-34 inhibits not
only PARP activity, but also other completely unrelated targets (as discussed earlier), such
as Pim-1 (IC50 = 3.7 μM) and Pim-2 (IC50 = 16 μM) serine/threonine kinases179 as well as
MMP-2 activity (IC50 = 56 μM).181 These findings raise concerns on the appropriateness of
using PJ-34 as a chemical tool for PARP biology studies at concentrations higher than 10 μM
in future studies.
E. INO-1001
Inotek Pharmaceutical Inc. (Beverly, MA, USA) has developed a potent lead compound INO-
1001 that exerts protective effects against atherosclerosis, myocardial infarction, stroke, and
chronic heart failure.25,185 INO-1001 is the most extensively studied PARP inhibitor for the
treatment of cardiovascular diseases. For example, in isolated aortic rings of ApoE−/− mice
kept on a HFD, Benko et al.130 provide the first line of experimental evidence showing the en-
dothelial protective and regressive effects of INO-1001. Subsequent evidence61,62 indicates that
INO-1001 improves endothelial dysfunction induced by myeloperoxidase-derived hypochlorite
and H2O2 in isolated normal aortic rings. A more recent study shows that INO-1001 reduces
atherosclerotic lesion development by modulating the activation of dendritic cells, T lympho-
cytes, and macrophages, concurrent with the reduction of the inflammatory responses within
the plaques.163 Pharmacological inhibition of PARP with INO-1001 prevents neointimal hy-
perplasia after endarterectomy in rats by reducing the neointima area, neutrophil infiltration,
nitrosative stress, and AIF nuclear translocation.186
F. Tetracycline Antibiotic and Bacteriostatic Agents
Tetracyclines are a group of naturally occurring and chemically synthesized pluripotent an-
timicrobial agents, the actions of which include potent inhibition of PARP1 enzymatic activity
(occurs at submicromolar concentrations), broad-spectrum MMPs inhibitory activity, and
anti-inflammatory activity.177 These activities contribute to the plaque inhibitory and stabi-
lizing effect of tetracyclines. The rank order of potencies for these compounds for inhibiting
recombinant PARP1 activity in a cell-free assay was minocycline > doxycycline > demeclo-
cycline > chlortetracycline.187 By comparison of the chemical structures, all the tetracycline
derivatives with demonstrated PARP1 inhibitory activity have a carboxamide and aromatic ring
structure (similar to the NAM moiety of NAD+), the pharmacophore shared by established
competitive PARP inhibitors.187 Among the tetracycline class, minocycline and doxycycline
have been evaluated extensively, in clinical as well as knockout and transgenic mouse studies, as
a possible therapy for atherosclerosis, ischemia-reperfusion injury, left ventricular remodeling,
restenosis, hypertension, heart failure, abdominal aortic aneurysms, and most importantly, for
patients with ACS.188–192 Mechanistically, selective inhibition of MMPs and PARP1 activity
conferred by tetracycline derivatives reduces inflammatory responses in atherosclerotic lesions,
prevents fibrous cap thinning, and, therefore, prevents the rupture of unstable atherosclerotic
plaques. Further studies are warranted to examine whether theMMPs inhibitory effect of these
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agents stems from direct PARP1 inhibition, and whether other tetracycline derivatives can
stabilize the unstable plaques and prevent the occurrence of ACS.193
6. PARP INHIBITORS IN CLINICAL TRIALS
PARP inhibitors have attracted intense attention as an effective therapeutic strategy for cancer
patients.43,194 Based on the structure–activity relationship of benzamide parent drugs, third
generation PARP inhibitors were developed through screening of chemical libraries and struc-
tural refining. Among these inhibitors, several compounds are promising entities, including
ABT-888 (Veliparib, Abbott Laboratories), AZD-2281 (Olaparib, KuDOS/AstraZeneca Phar-
maceuticals), INO-1001 (Inotek Pharmaceuticals), AG-014699 (Rucaparib, Pfizer), MK-4827
(Niraparib, Merck), and CEP-9722 (Cephalon). These inhibitors are now in different stages of
clinical development either as single therapy for homologous recombination repair-deficient
(for example, BRCA1- or BRCA2-deficient) cancers and sporadic cancers; or in combination
therapy with standard DNA-damaging chemotherapy and radiotherapy.43,194,195 In 2005, the
US Food and Drug Administration granted the request of Inotek Pharmaceuticals for orphan
drug designation for INO-1001, for the prevention of the postoperative complications of aortic
aneurysm repair surgery. In addition to the aortic aneurysm repair indication, INO-1001
has been evaluated in Phase II clinical trials as a drug to protect the heart during cardiopul-
monary bypass surgery as well as for angioplasty procedures after myocardial infarction
(ClinicalTrials.gov identifier: NCT00271765, NCT00271167). It remains, however, elusive
whether other PARP inhibitors in clinical development will reduce plaque burden in patients
with atherosclerosis.
7. CONCLUDING REMARKS AND FUTURE PERSPECTIVES
Over the past decade, great strides have been made toward characterizing the underlying
molecular mechanisms of PARP1 activation. Emerging evidence demonstrates that PARP ac-
tivation (PARP1 in particular) is critically involved in atherosclerotic plaque formation and
destabilization. The use of PARP inhibitors is beneficial not only in preventing atherogen-
esis, but also in promoting the regression of previously established atherosclerotic plaques.
However, many questions remain to be addressed: (i) What are the diverse roles of the less
well-characterized PARP family members in atherosclerosis? Cell-type-specific knockout mice
for particular PARPs are required to clarify this issue. (ii) What are the substrates of PARP1
in the context of atherosclerosis and how will the PARylation of these substrates affect the de-
velopment of atherosclerosis? PARylated substrates identified in pull-down experiments using
macrodomain proteins196,197 coupled with phosphoproteomics-based mass spectrometry33,198
will yield valuable information on this issue. (iii) How to design effective therapeutic agents
aiming to remove PAR from target proteins in atherosclerosis? (iv) Is it possible to regulate
PARP1 activity via their interactors (e.g., resetting the PARP1–SIRT1 activity balance)? (v)Will
PARP inhibitors exhibit therapeutic utility in combination with other therapeutic modalities of
atherosclerosis (such as statins, Ang-converting enzyme inhibitors, Ang-II receptor blockers)?
(vi) When planning the application of PARP inhibitors in patients with atherosclerosis, the
risk/benefit ratio of the long-term administration of PARP inhibitors must be considered. This
is particularly important in the setting of atherosclerosis—a chronic inflammatory disease that
typically requires long-term therapeutic administration, but it represents a significantly higher
drug development/toxicology challenge than short-term administration of PARP inhibitors
for acute indications.25,177 The safety and risks associated with long-term administration of
Medicinal Research Reviews DOI 10.1002/med
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PARP inhibitors are associated with the regulatory role of PARPs in DNA repair and genomic
integrity.96,195 Taken together, the discoveries reviewed here provide novel insights into the
rational design of PARP-targeting drugs, and depict an upcoming translational era of PARP
inhibitors in the clinical management of atherosclerotic cardiovascular diseases.
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